Amphastar Pharmaceuticals (AMPH) Receivables (2013 - 2026)

Amphastar Pharmaceuticals has reported Receivables for 14 years, with the latest figure at $145.8 million in Q2 2026.

• On a quarterly basis, Receivables rose 9.2% year-over-year to $145.8 million in Q2 2026; TTM through Jun 2026 was $145.8 million, a 9.2% increase from a year earlier, with the FY2025 full-year figure at $143.6 million, up 5.18% from the prior year.
• Receivables was $145.8 million for Q2 2026 at Amphastar Pharmaceuticals, down from $148.5 million in the prior quarter.
• The five-year high for Receivables was $148.5 million in Q1 2026, with the low at $73.2 million in Q1 2022.
• Average Receivables over 5 years is $120.6 million, with a median of $132.6 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables retreated 6.12% in 2022, then surged 53.93% in 2023.
• Over 5 years, Receivables stood at $89.2 million in 2022, then increased by 28.85% to $114.9 million in 2023, then grew by 18.74% to $136.5 million in 2024, then increased by 5.18% to $143.6 million in 2025, then advanced by 1.53% to $145.8 million in 2026.
• The last three Receivables figures came in at $145.8 million (Q2 2026), $148.5 million (Q1 2026), and $143.6 million (Q4 2025), per Business Quant data.